A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
- Conditions
- Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- Interventions
- Registration Number
- NCT06134804
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) does not induce lower antibody response against each of the 4 influenza vaccine strains, as compared to HD QIV given alone and further show that ExPEC9V given together with HD QIV does not induce lower antibody response against each of the vaccine O-serotype antigens, as compared to ExPEC9V given alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 959
- Must be medically stable at the time of vaccination such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy during the 6 weeks before enrollment and when hospitalization for worsening of the disease is not anticipated. Participants will be included on the basis of physical examination, medical history, and vital signs performed between informed consent form (ICF) signature and vaccination
- Participant must be: a) postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and b) not intending to conceive by any methods
- Must sign an ICF indicating that the participant understands the purpose, procedures and potential risks and benefits of the study, and is willing to participate in the study
- Willing and able to adhere to the lifestyle restrictions specified in this protocol
- Agrees to not donate blood from the time of vaccination until 3 months after receiving the last dose of study vaccine
- History of an underlying clinically significant acute or uncontrolled chronic medical condition or significant cognitive impairment or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- Known or suspected allergy or history of severe allergic reaction, anaphylaxis, or other serious adverse reactions to vaccines or vaccine excipients
- History of severe allergic reactions (for example anaphylaxis) to any component of the high-dose (HD) quadrivalent seasonal influenza vaccine, including egg protein, or following a previous dose of any influenza vaccine
- Has had major surgery (per the investigator's judgment) within 4 weeks before administration of the first study vaccine or will not have recovered from surgery per the investigator's judgment at time of vaccination
- History of acute polyneuropathy (for example, Guillain-Barré syndrome) or chronic inflammatory demyelinating polyneuropathy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 1: Coadministration (CoAd) Group ExPEC9V Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30. Group 2: Control Group ExPEC9V Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30. Group 2: Control Group Placebo Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30. Group 1: Coadministration (CoAd) Group Placebo Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30. Group 1: Coadministration (CoAd) Group HD quadrivalent influenza vaccine Participants will receive intramuscular (IM) injection of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) along with high-dose (HD) quadrivalent influenza vaccine, concomitantly, on Day 1 and placebo on Day 30. Group 2: Control Group HD quadrivalent influenza vaccine Participants will receive IM injection of matching placebo along with HD quadrivalent influenza vaccine, concomitantly, on Day 1 and ExPEC9V on Day 30.
- Primary Outcome Measures
Name Time Method Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Electrochemiluminescent (ECL)-based Immunoassay 29 days After Administration of ExPEC9V on Day 1 29 days after administration of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) on Day 1 (Day 30) Antibody titers to vaccine O-serotype antigens as determined by multiplex ECL-based immunoassay 29 days after administration of ExPEC9V on Day 1 will be reported.
Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Four Influenza Vaccine Strains as Measured by HI Assay 29 days after High-dose (HD) quadrivalent influenza vaccination on Day 1 (Day 30) HI antibody titers measured by HI assay against each of the four influenza vaccine strains will be reported.
Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Electrochemiluminescent (ECL)-based Immunoassay 29 days After Administration of ExPEC9V on Day 30 29 days after administration of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) on Day 30 (Day 59) Antibody titers to vaccine O-serotype antigens as determined by multiplex ECL-based immunoassay 29 days after administration of ExPEC9V on Day 30 will be reported.
- Secondary Outcome Measures
Name Time Method Percentage of Seroprotected Participants 29 days after HD quadrivalent influenza vaccination on Day 1 (Day 30) Percentage of seroprotected participants will be reported. Seroprotection is defined for each of the 4 influenza vaccine strains as HI titer \>=1:40 at 29 days after the administration of a HD quadrivalent seasonal influenza vaccine.
Antibody Titers to Vaccine O-serotype Antigens and Exotoxin a Derived from Pseudomonas Aeruginosa (EPA) as Determined by Multiplex ECL-based Immunoassay At days 1, 30, and 59 Antibody titers to vaccine O-serotype antigens and EPA as determined by multiplex ECL-based immunoassay will be reported.
Percentage of Participants with Serious Adverse Events (SAEs) From Vaccination 1 to Until 6 Months After Vaccination 2 From vaccination 1 (on Day 1) till 6 months after vaccination 2 (on Day 30), that is until Day 210 A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly; is a suspected transmission of any infectious agent through a medicinal product; and is medically important.
Percentage of Seroconverted Participants 29 days after HD quadrivalent influenza vaccination on Day 1 (Day 30) Percentage of seroconverted participants will be reported. Seroconversion is defined for each of the 4 influenza vaccine strains at 29 days after the administration of a HD quadrivalent seasonal influenza vaccine: 1) HI titer greater than or equal to (\>=) 1:40 in participants with a pre-vaccination HI titer of less than (\<) 1:10, or 2) a \>=4-fold HI titer increase in participants with a pre-vaccination HI titer of \>=1:10.
Percentage of Participants with Solicited Local (Injection Site) Adverse Events (AEs) for 14 Days After Each Vaccination 14 days post-vaccination 1 on Day 1 (Day 15) and post-vaccination 2 on Day 30 (Day 44) Percentage of participants with solicited local (injection site) AEs for 14 Days after each vaccination will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the study vaccination. Solicited local AEs are used to assess the reactogenicity of the study vaccine and are pre-defined local (injection site) and systemic events for which participants will be specifically questioned and which will be noted by participants in their participant diary for 14 days post vaccination (day of vaccination and the subsequent 14 days). Solicited local AEs are: injection site pain or tenderness, erythema and swelling at the study vaccine injection site. Solicited local AEs are considered related to study vaccine administration.
Percentage of Participants with Solicited Systemic AEs for 14 Days After Each Vaccination 14 days post-vaccination 1 on Day 1 (Day 15) and post-vaccination 2 on Day 30 (Day 44) Percentage of participants with solicited systemic AEs for 14 Days after each vaccination will be reported. Solicited systemic AEs include following events: fatigue, headache, nausea, myalgia, and fever. Participants will be instructed on how to note signs and symptoms in the participant diary on a daily basis for 14 days post-vaccination (day of vaccination and the subsequent 14 days) for these events.
Percentage of Participants with Unsolicited AEs for 29 Days After Each Vaccination 29 days post-vaccination 1 on Day 1 (Day 30) and post-vaccination 2 on Day 30 (Day 59) Percentage of participants with unsolicited AEs for 29 days after each vaccination will be reported. Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant diary.
Percentage of Participants with Medically-attended Adverse Events (MAAEs) From Vaccination 1 to Until 6 Months After Vaccination 2 From vaccination 1 (on Day 1) till 6 months after vaccination 2 (on Day 30), that is until Day 210 MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. AEs (for example, abnormal vitals) identified at a routine study visit will not be considered MAAEs.
Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Opsonophagocytic Assay (MOPA) 29 Days After Administration of ExPEC9V on Day 1 (Day 30) 29 days after administration of ExPEC9V on Day 1 (Day 30) Opsonophagocytic antibody titers to vaccine O-serotype antigens as determined by MOPA 29 Days after administration of ExPEC9V on Day 1 (Day 30) will be reported.
Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex ECL-based Immunoassay 29 days after administration of ExPEC9V on Day 1 (Day 30) in participants with or without History of Urinary Tract Infection (UTI) at Enrollment 29 days after administration of ExPEC9V on Day 1 (Day 30) Antibody titers to vaccine O-serotype antigens as determined by multiplex ECL-based Immunoassay will be reported 29 days after administration of ExPEC9V on Day 1 (Day 30) in participants with a history of UTI at enrollment and participants without a UTI history at enrollment
Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex Opsonophagocytic Assay (MOPA) 29 Days After Administration of ExPEC9V on Day 30 (Day 59) 29 days after administration of ExPEC9V on Day 30 (Day 59) Opsonophagocytic antibody titers to vaccine O-serotype antigens as determined by MOPA 29 Days after administration of ExPEC9V on Day 30 (Day 59) will be reported.
Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens as Determined by MOPA 29 days after administration of ExPEC9V on Day 1 (Day 30) in participants with or without History of UTI at Enrollment 29 days after administration of ExPEC9V on Day 1 (Day 30) Opsonophagocytic antibody titers to vaccine O-serotype antigens as determined by MOPA 29 days after administration of ExPEC9V on Day 1 (Day 30) will be reported in participants with a history of UTI at enrollment and participants without a UTI history at enrollment.
Antibody Titers to Vaccine O-serotype Antigens as Determined by Multiplex ECL-based Immunoassay 29 days after administration of ExPEC9V on Day 30 (Day 59) in participants with or without History of Urinary Tract Infection (UTI) at Enrollment 29 days after administration of ExPEC9V on Day 30 (Day 59) Antibody titers to vaccine O-serotype antigens as determined by multiplex ECL-based Immunoassay will be reported 29 days after administration of ExPEC9V on Day 30 (Day 59) in participants with a history of UTI at enrollment and participants without a UTI history at enrollment
Opsonophagocytic Antibody Titers to Vaccine O-serotype Antigens as Determined by MOPA 29 days after administration of ExPEC9V on Day 30 (Day 59) in participants with or without History of UTI at Enrollment 29 days after administration of ExPEC9V on Day 30 (Day 59) Opsonophagocytic antibody titers to vaccine O-serotype antigens as determined by MOPA 29 days after administration of ExPEC9V on Day 30 (Day 59) will be reported in participants with a history of UTI at enrollment and participants without a UTI history at enrollment.
Trial Locations
- Locations (34)
Synexus Polska Sp z o o Oddzial w Katowicach
🇵🇱Katowice, Poland
Medical Affiliated Research Center Inc. (MARC)
🇺🇸Huntsville, Alabama, United States
Alliance for Multispeciality Research
🇺🇸Knoxville, Tennessee, United States
Artemis Institute for Clinical Research
🇺🇸San Diego, California, United States
Diablo Clinical Research, Inc.
🇺🇸Walnut Creek, California, United States
Optimal Research
🇺🇸Austin, Texas, United States
Pharmax Research Clinic Inc
🇺🇸Miami, Florida, United States
Suncoast Research Associates, LLC
🇺🇸Miami, Florida, United States
Atlanta Center for Medical Research
🇺🇸Atlanta, Georgia, United States
Velocity Clinical Research
🇺🇸East Greenwich, Rhode Island, United States
Synexus Clinical Research US Inc
🇺🇸Creve Coeur, Missouri, United States
Synexus Radiant Research, Inc
🇺🇸Evansville, Indiana, United States
Heartland Research Associates, LLC
🇺🇸Newton, Kansas, United States
Heartland Research Associates, an AMR Company
🇺🇸Wichita, Kansas, United States
Accellacare
🇺🇸Wilmington, North Carolina, United States
CTI Clinical Trial and Consulting Services
🇺🇸Cincinnati, Ohio, United States
Benchmark Clinical Research - Austin
🇺🇸Austin, Texas, United States
Tekton Research Inc.
🇺🇸Beaumont, Texas, United States
Universiteit Antwerpen - Centrum voor de Evaluatie van Vaccinaties (CEV)
🇧🇪Edegem, Belgium
Center for Vaccinology (CEVAC)
🇧🇪Gent, Belgium
Az Sint-Maarten
🇧🇪Mechelen, Belgium
Aggarwal and associates Ltd
🇨🇦Brampton, Ontario, Canada
Milestone Research
🇨🇦London, Ontario, Canada
Centricity Research- Manna Research (MR) - Quebec Location
🇨🇦Levis, Quebec, Canada
Synexus Polska Sp. z o.o. Oddzial w Gdansku
🇵🇱Gdansk, Poland
PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p.
🇵🇱Gdansk, Poland
Synexus Polska Sp. z o.o. Oddzial w Gdynia
🇵🇱Gdynia, Poland
Pratia MCM Krakow
🇵🇱Krakow, Poland
Velocity Lublin
🇵🇱Lublin, Poland
Velocity Staszow
🇵🇱Staszow, Poland
MICS Centrum Medyczne Torun
🇵🇱Torun, Poland
MICS Centrum Medyczne Warszawa
🇵🇱Warszawa, Poland
Synexus Polska Sp z o o Oddzial w Warszawie
🇵🇱Warszawa, Poland
Synexus Polska Sp z o o Oddzial we Wroclawiu
🇵🇱Wroclaw, Poland